Long-term prognosis and causes of death in systemic lupus erythematosus

被引:272
作者
Doria, Andrea
Iaccarino, Luca
Ghirardello, Anna
Zampieri, Sandra
Arienti, Silvia
Sarzi-Puttini, Piercarlo
Atzeni, Fabiola
Piccoli, Antonio
Todesco, Silvano
机构
[1] Univ Padua, Div Rheumatol, Dept Clin & Expt Med, I-35128 Padua, Italy
[2] Sacco Univ Hosp, Rheumatol Unit 1, Milan, Italy
[3] Univ Padua, Dept Med & Surg Sci, Div Nephrol, I-35128 Padua, Italy
关键词
systemic lupus erythematosus; survival; mortality; prognosis; environmental factors; lupus nephritis; severe disease;
D O I
10.1016/j.amjmed.2005.11.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: We studied survival rate, prognostic factors, and causes of death in patients with systemic lupus erythematosus (SLE), particularly focusing on the influence of disease severity. PATIENTS AND METHODS: A cohort of 207 consecutive Italian patients with SLE were prospectively studied. All prominent clinical and serologic parameters were evaluated and considered as prognostic risk factors. Causes of death were defined on the basis of clinical data and, when available, postmortem examination. Survival was calculated from the time of diagnosis by Kaplan-Meier method. RESULTS: A total of 17 of 207 patients died; causes of death were active disease manifestations in 35.3% of cases and complication of the disease or its treatment in 64.7% of cases. The survival rates at 5, 10, and 15 years after the diagnosis were 96%, 93% and 76%, respectively. By multivariate analysis of the risk factors, a predictive model consisting of male gender, positive lupus anticoagulant, and "severe" SLE was identified. The survival curve of the patients with severe disease was similar to that of patients with mild disease until 10 to 15 years from the diagnosis. Thereafter the two curves tended to diverge, showing a clear survival decline in patients with severe disease. CONCLUSIONS: Our study confirms the increase of short- and medium-term survival in patients with SLE, but long-term prognosis remains poor in patients with severe SLE manifestations. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:700 / 706
页数:7
相关论文
共 43 条
[1]   Systemic lupus erythematosus and cancer: associated or not? [J].
Abu-Shakra, M ;
Ehrenfeld, M ;
Shoenfeld, Y .
LUPUS, 2002, 11 (03) :137-144
[2]  
ABUSHAKRA M, 1995, J RHEUMATOL, V22, P1259
[3]   Survival and mortality rates of systemic lupus erythematosus patients in northwest Greece. Study of a 21-year incidence cohort [J].
Alamanos, Y ;
Voulgari, PV ;
Parassava, M ;
Tsamandouraki, K ;
Drosos, AA .
RHEUMATOLOGY, 2003, 42 (09) :1122-U17
[4]  
[Anonymous], 1990, BMDP STAT SOFTWARE M
[5]  
Bellomio V, 2000, LUPUS, V9, P377
[6]   Exploring the links between systemic lupus erythematosus and cancer [J].
Bernatsky, S ;
Ramsey-Goldman, R ;
Clarke, A .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2005, 31 (02) :387-+
[7]   An International Cohort Study of Cancer in Systemic Lupus Erythematosus [J].
Bernatsky, S ;
Boivin, JF ;
Joseph, L ;
Rajan, R ;
Zoma, A ;
Manzi, S ;
Ginzler, E ;
Urowitz, M ;
Gladman, D ;
Fortin, PR ;
Petri, M ;
Edworthy, S ;
Barr, S ;
Gordon, C ;
Bae, SC ;
Sibley, J ;
Isenberg, D ;
Rahman, A ;
Aranow, C ;
Dooley, MA ;
Steinsson, K ;
Nived, O ;
Sturfelt, G ;
Alarcón, G ;
Senécal, JL ;
Zummer, M ;
Hanly, J ;
Ensworth, S ;
Pope, J ;
El-Gabalawy, H ;
McCarthy, T ;
Pierre, YS ;
Ramsey-Goldman, R ;
Clarke, A .
ARTHRITIS AND RHEUMATISM, 2005, 52 (05) :1481-1490
[8]   Malignancy and systemic lupus erythematosus. [J].
Bernatsky S. ;
Clarke A. ;
Ramsey-Goldman R. .
Current Rheumatology Reports, 2002, 4 (4) :351-358
[9]   Survival analysis of 306 European Spanish patients with systemic lupus erythematosus [J].
Blanco, FJ ;
Gomez-Reino, JJ ;
de la Mata, J ;
Corrales, A ;
Rodriguez-Valverde, V ;
Rosas, JC ;
de la Camara, AG ;
Pascual, E .
LUPUS, 1998, 7 (03) :159-163
[10]   Risk factors for coronary heart disease in women with systemic lupus erythematosus -: The Toronto Risk Factor Study [J].
Bruce, IN ;
Urowitz, MB ;
Gladman, DD ;
Ibañez, D ;
Steiner, G .
ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3159-3167